CN Patent

CN115698004A — 作为hpk1抑制剂的氮杂内酰胺化合物

Assigned to Pfizer Inc · Expires 2023-02-03 · 3y expired

What this patent protects

本发明涉及通式I化合物及其药学上可接受的盐， 其中R 1 、R 2 、R3 a 、R 3b 和R 4 如本文所定义；包含此类化合物及盐的药物组合物；以及使用此类化合物、盐和组合物治疗包括癌症的异常细胞生长的方法。

USPTO Abstract

本发明涉及通式I化合物及其药学上可接受的盐， 其中R 1 、R 2 、R3 a 、R 3b 和R 4 如本文所定义；包含此类化合物及盐的药物组合物；以及使用此类化合物、盐和组合物治疗包括癌症的异常细胞生长的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN115698004A
Jurisdiction
CN
Classification
—
Expires
2023-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.